Head to Head Comparison: Flexion Therapeutics (FLXN) & Its Competitors

Flexion Therapeutics (NASDAQ: FLXN) is one of 282 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Flexion Therapeutics to similar businesses based on the strength of its valuation, risk, analyst recommendations, dividends, profitability, earnings and institutional ownership.

Earnings & Valuation

This table compares Flexion Therapeutics and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Flexion Therapeutics N/A -$71.89 million -6.76
Flexion Therapeutics Competitors $286.20 million $34.74 million 141.71

Flexion Therapeutics’ competitors have higher revenue and earnings than Flexion Therapeutics. Flexion Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


This table compares Flexion Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Flexion Therapeutics N/A -60.29% -38.08%
Flexion Therapeutics Competitors -5,323.56% -476.38% -40.13%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Flexion Therapeutics and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Flexion Therapeutics 0 1 7 1 3.00
Flexion Therapeutics Competitors 800 3160 11456 229 2.71

Flexion Therapeutics presently has a consensus price target of $98.33, indicating a potential upside of 315.61%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.59%. Given Flexion Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Flexion Therapeutics is more favorable than its competitors.

Risk and Volatility

Flexion Therapeutics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Flexion Therapeutics’ competitors have a beta of 1.51, suggesting that their average stock price is 51% more volatile than the S&P 500.

Insider and Institutional Ownership

69.2% of Flexion Therapeutics shares are owned by institutional investors. Comparatively, 49.9% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.0% of Flexion Therapeutics shares are owned by company insiders. Comparatively, 17.2% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


Flexion Therapeutics beats its competitors on 8 of the 12 factors compared.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company’s other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply